URC-ECO, Hotel-Dieu Hospital, AP-HP, Paris, France.
Department of Infectious and Tropical Diseases, University Hospital, Nantes, France.
PLoS One. 2024 Sep 30;19(9):e0308784. doi: 10.1371/journal.pone.0308784. eCollection 2024.
An oral two-drug regimen (O2DR) in the form of a once-a-day single tablet is now recommended for treatment switching and treatment initiation for HIV. In clinical care, the process of treatment change refers to adaptation issues, both individual and within the care relationship. The study aim is to present the determinants involved in the acceptability of switching to O2DR in the PROBI (Patient-Reported Outcomes BItherapy) qualitative study. The study includes 30 interviews: 15 were conducted with doctors caring for people living with HIV, 15 were conducted with patients who had been offered a change of treatment. A double analysis was carried out: lexicometric analysis to highlight the structuring of the discourse around the change in treatment and a thematic analysis to understand the associated issues more precisely. The results highlighted common concerns with respect to switching to O2DR. Also, the caregiver-patient relationship was a central determinant in treatment switching. Information, knowledge and representations of O2DR are also factors facilitating treatment change and should be taken into account for doctors' and patients' adherence.
目前推荐将一种每日一次的单片口服两药方案作为治疗转换和起始治疗的选择。在临床护理中,治疗改变的过程涉及个体和护理关系中的适应问题。本研究旨在通过 PROBI(患者报告结局 BI 治疗)定性研究呈现与接受 O2DR 治疗转换相关的决定因素。该研究包括 30 次访谈:15 次与照顾艾滋病毒感染者的医生进行,15 次与接受治疗转换的患者进行。进行了双重分析:词汇分析突出了围绕治疗变化的话语结构,主题分析更准确地理解相关问题。结果突出了与转换为 O2DR 相关的共同关注点。此外,医患关系是治疗转换的一个关键决定因素。O2DR 的信息、知识和表象也是促进治疗改变的因素,应考虑到医生和患者的坚持。